| BAI Peng-gang,LI Qi-xin,CHEN Kai-qiang,ZHANG Xiu-chun,WANG Ya-zhi,HUANG Xing-wu.Dosimetric verification of volumetric modulated arc therapy in nasopharyngeal carcinoma using COMPASS 3D patient anatomy based system[J].Chinese Journal of Radiological Medicine and Protection,2012,32(3):304-307 |
| Dosimetric verification of volumetric modulated arc therapy in nasopharyngeal carcinoma using COMPASS 3D patient anatomy based system |
| Received:July 21, 2011 |
| DOI：10.3760/cma.j.issn.0254-5098.2012.03.021 |
| KeyWords:COMPASS system Volumetric modulated arc therapy Dosimetric verification |
| FundProject: |
| Author Name | Affiliation | E-mail | | BAI Peng-gang | Department of Radiation Oncology, Fujian Tumor Hospital, Fuzhou 350014, China | | | LI Qi-xin | Department of Radiation Oncology, Fujian Tumor Hospital, Fuzhou 350014, China | liqixin1982@hotmail.com | | CHEN Kai-qiang | Department of Radiation Oncology, Fujian Tumor Hospital, Fuzhou 350014, China | | | ZHANG Xiu-chun | Department of Radiation Oncology, Fujian Tumor Hospital, Fuzhou 350014, China | | | WANG Ya-zhi | 福建省泉州一八零医院放疗科 | | | HUANG Xing-wu | Department of Radiation Oncology, Fujian Tumor Hospital, Fuzhou 350014, China | |
|
| Hits: 3794 |
| Download times: 2470 |
| Abstract:: |
| Objective To investigate the dosimetric performance of COMPASS system, a novel 3D quality assurance system for the verification of nasopharyngeal carcinoma volumetric modulated therapy (VMAT) treatment plan.Methods Eight VMAT treatment plans of nasopharyngeal carcinoma patients were performed with MasterPlan, a treatment planning system (TPS), and then these treatment plans were sent to the COMPASS and MOSAIQ system, a coherent control system, respectively. Comparison of the COMPASS reconstructed dose versus TPS dose was conducted by using the dose volume-based indices: dose received by 95% volume of target (D95%), mean dose (Dmean) and γ pass rate, dose to the 1% of the spinal cord and brain stem volume (D1%), mean dose of leaf and right parotid (Dmean), and the volume received 30 Gy for left and right parotid (V30). COMPASS can reconstruct dose with the real measured delivery fluence after detector commissioning.Results The average dose difference for the target volumes was within 1%, the difference for D95 was within 3% for most treatment plans, and the γ pass rate was higher than 95% for all target volumes. The average differences for the D1% values of spinal cord and brain stem were (4.3±3.0)% and (5.9±2.9)% respectively, and the average differences for the Dmean values of spinal cord and brain stem were (5.3±3.0)% and (8.0±3.5)% respectively. In general the COMPASS measured doses were all smaller than the TPS calculated doses for these two organs. The average differences of the Dmean values of the left and right parotids were (6.1±3.1)% and(4.7±4.4)% respectively, and the average differences of the V30 values of the left and right parotids were (9.4±7.5)% and (9.4±9.9)% respectively.Conclusions An ideal tool for the VMAT verification, the patient anatomy based COMPASS 3D dose verification system can check the dose difference between the real delivery and TPS calculation directly for each individual organ, either target volumes or critical organs. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
